
Weight Loss in 40s or 50s? Slash Your Chronic Disease Risk
People who reduce excess weight in midlife can roughly halve their risk of developing chronic disease later in life. That's the conclusion of three long-term studies from the UK and Finland, analyzed by a team led by Timo E. Strandberg, MD, PhD, professor of geriatrics at the University of Helsinki, Helsinki, Finland, and chief physician at its university hospital.
The findings, based on more than 23,000 participants, were published in JAMA Network Open .
Although the negative effects of obesity on health are well known, 'Few studies have examined long-term health benefits among individuals with sustained weight loss beyond its association with decreased diabetes risk,' wrote Strandberg and colleagues. Their analysis also looked at heart attack, stroke, cancer, asthma, chronic obstructive pulmonary disease, and overall mortality.
No Weight-Loss Drugs or Surgery Needed
'This publication again powerfully demonstrates that people have a large degree of control over their own health and can protect themselves from many illnesses — including age-related diseases — by preventing or reducing excess weight,' said Stephan Martin, MD, chief physician for diabetology of the Catholic Hospital Group Düsseldorf and director of the West-German Centre of Diabetes and Health, Düsseldorf, Germany, in an interview with Medscape's German edition .
'Another encouraging takeaway is that these results were achieved without weight-loss injections or surgical interventions,' Martin added.
Commenting on the analysis, Ga Eun Nam, MD, PhD, of Korea University College of Medicine in Seoul, Republic of Korea, and Yong-Moon Park, MD, PhD, of the University of Arkansas for Medical Sciences in Little Rock, Arkansas, noted that individuals who reached a healthy weight in midlife had long-term health outcomes comparable with those who maintained a healthy weight throughout adulthood.
Martin put it more simply: 'It's always worth losing weight.' Even those who reach a normal weight at 50 — or later — can still see health benefits.
Follow-Up Spanning Several Decades
Strandberg and his team evaluated three longitudinal studies that included repeated measurements of height and weight:
The Whitehall II Study, launched in 1985 (4118 participants; 72.1% men)
The Helsinki Businessmen Study, launched in 1964 (2335 male participants)
The Finnish Public Sector Study, with data starting from 2000 (16,696 participants; 82.6% women)
The follow-up periods ranged from 12 to 35 years.
Participants, with an average starting age of about 40, were divided into four groups:
Those with consistently normal weight (BMI < 25)
Those who reduced from overweight to normal weight
Those who gained weight (normal to overweight)
Those who remained overweight (BMI ≥ 25)
Diabetes Risk Not the Only One Reduced
In the Whitehall II Study, with an average follow-up of 22.8 years, a BMI reduction from ≥ 25 to < 25 over approximately 6 years in midlife was associated with a lower risk of developing chronic diseases.
After adjusting for potential confounders such as smoking, blood pressure, and lipid levels, the researchers calculated a 48% lower risk for chronic illness compared to those who remained overweight. Remarkably, this association held even after excluding participants who developed diabetes during follow-up. In that case, the risk reduction was 42%.
The Finnish Public Sector Study, with a 12.2-year follow-up, confirmed the findings, showing a 57% reduced risk for chronic illness.
Effects Independent of Gender and Hormonal Status
The Helsinki Businessmen Study, which had the longest follow-up (up to 43 years; mean, 35 years), showed that weight loss in midlife was associated with a 19% reduction in overall mortality.
Separate analyses by sex revealed that the association held for both men and women. Even menopausal status did not significantly affect the outcomes: Similar protective effects were observed in women younger and older than 50 years.
Midlife as a Critical Window for Intervention
'As we continue facing the global obesity epidemic, this study provides valuable epidemiologic evidence on long-term associations between weight management and major health outcomes,' wrote Nam and Park. While further research is needed to refine intervention strategies, 'these results highlight midlife as a potentially critical window for weight management and reinforce the importance of sustained weight management in chronic disease prevention and longevity.'
The study was conducted in a time when neither surgical nor pharmacologic weight loss interventions were common. 'Sustained midlife weight loss compared with persistent overweight was associated with a decreased risk of chronic diseases beyond type 2 diabetes and decreased all-cause mortality,' Strandberg and colleagues concluded.
Diet as the Main Lever
Martin said the findings confirm the importance of lifestyle in achieving and maintaining a healthy weight.
'Most chronic diseases caused by obesity stem from lack of physical activity and poor diet,' he noted. Foods that spike blood glucose and insulin levels should be avoided. 'Insulin inhibits fat breakdown, so it contributes to weight gain,' he explained.
A long-term strategy for staying lean and healthy, Martin said, includes minimizing intake of white bread, fries, chips, chocolate, soda, and other highly processed foods.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
23 minutes ago
- Medscape
Integrating CAR T and Bispecific Antibodies in MM Treatment
MILAN — The treatment landscape for relapsed and refractory multiple myeloma (RRMM) has shifted dramatically with the emergence of immunotherapies such as chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies (bsAbs). These novel approaches have delivered unprecedented outcomes in heavily pretreated patients. Yet determining the optimal treatment strategy remains a clinical challenge. Here at the 2025 European Hematology Association (EHA) Annual Meeting in Milan, Italy, leading experts weighed the strengths and limitations of both approaches, emphasizing that it is not a contest of superiority but a question of sequence and patient selection. Bispecific Antibodies: Off-the-Shelf Convenience With Strong Responses BsAbs work by redirecting T cells toward myeloma cells, binding simultaneously to a tumor antigen and CD3. In his presentation, Philippe Moreau, MD, head of the hematology department at the University Hospital of Nantes, France, reviewed the four agents approved in Europe: teclistamab, elranatamab, and linvoseltamab, which target beta cell maturation antigen (BCMA); and talquetamab, which targets G protein-coupled receptor class C group 5 member D (GPRC5D). These agents deliver overall response rates (ORRs) of 60%-70% in heavily pretreated patients, with median progression-free survival (PFS) of 12-18 months and overall survival (OS) of 24-30 months. Talquetamab in particular induces rapid responses within 1 month but is associated with unique toxicities — such as skin reactions, dysgeusia, and mucosal effects — related to GPRC5D expression in nonhematopoietic tissues like skin. BsAbs offer immediate treatment without the delays associated with CAR T manufacturing. They are also viable for frail patients and more broadly accessible outside of specialized centers. Toxicities, including cytokine release syndrome and infections, are generally manageable with step-up dosing and prophylactic tocilizumab. However, resistance remains a main concern. Roughly one third of patients — particularly those with high-risk cytogenetics, International Staging System stage III disease, or extramedullary disease — exhibit primary resistance. CAR T-Cell Therapy: Durable Outcomes With Earlier Use CAR T-cell therapies have redefined expectations in RRMM, particularly with ciltacabtagene autoleucel, which has achieved a median PFS of 35 months and a median OS approaching 61 months in heavily pretreated populations. Notably, recent data show that one third of patients remain progression-free at 5 years: an unprecedented milestone. 'Phase 3 trials now show improved PFS, OS, and quality of life compared to standard-of-care regimens,' said Paula Rodriguez-Otero, MD, medical coordinator of the Central Unit for Clinical Trials at the University of Navarra, Pamplona, Spain. However, CAR T therapy faces logistical hurdles, including manufacturing delays and the need for specialized infrastructure. High-risk patients with rapid progression or poor bridging therapy responses may still experience suboptimal results, but these challenges are mitigated when CAR T therapy is used earlier in the disease course, before T-cell exhaustion occurs. It's Not One or the Other Both speakers agreed that the future of MM treatment is not about choosing between CAR T and bsAbs but about defining the optimal sequence and integrating both modalities based on patient needs and disease features. BsAbs offer fast, outpatient-ready options for frail or rapidly progressing patients. CAR T therapies, though more complex, offer long remissions and potential treatment-free intervals, especially when used early. Still, Moreau cautioned, many questions remain. What is the best treatment sequence? Should clinicians switch targets — for example from BCMA to GPRC5D — or stick with the same? How should resistance mechanisms, such as antigen loss, be tackled? Can we move toward fixed-duration therapy to reduce costs? Scientific progress must also account for patient priorities. As Solène Clavreul, PhD, noted in an interview with Medscape Medical News , longer survival for myeloma patients means that quality of life is increasingly central. Clavreul is patient advocate and head of medical education and scientific engagement at Myeloma Patients Europe. 'The treatment choices should always be based on research data, but understanding patients' preferences is critical for shared decision-making,' she said. What's Next: BsAb Combinations and Trispecifics 'With 19 new drugs or combinations approved in the past two decades, we've made incredible progress,' said Jesús San Miguel Izquierdo, MD, PhD, director of clinical and translational medicine at the University of Navarra, Pamplona, Spain, in his EHA 2025 Lifetime Achievement Award lecture. Two industry-sponsored studies presented at EHA 2025 point to the next wave of innovation. RedirecTT-1: Dual-Antigen BsAb Combination The phase 2 RedirecTT-1 trial evaluated the combination of talquetamab and teclistamab in patients with extramedullary disease. 'Patients with true extramedullary disease are up to 87% less likely to respond to conventional therapy,' said Shaji Kumar, MD, consultant, professor, and researcher at the Mayo Clinic, Rochester, USA. The combination treatment in the trial yielded an ORR of 78.9% and a complete response rate of 54.4%, with a 12-month PFS rate of 61% and OS rate of 74.5%. Adverse events were not significantly higher than in monotherapy trials, and less frequent dosing (biweekly or monthly) improved tolerability. 'These results showed deep and durable responses in a population with a significant unmet need,' Kumar said. Moreau, who was not involved in the study, added, 'This could be the pivotal trial that leads to approval of the first bsAb combination.' JNJ-5322: First-in-Human Trispecific Antibody JNJ-5322, a trispecific antibody targeting both BCMA and GPRC5D, showed remarkable efficacy in BCMA/GPRC5D-naive patients in a phase 1 trial. 'Despite recent progress, we still need to reduce treatment burden and improve outcomes,' said Rakesh Popat, MD, hematologist at University College Hospital, London, UK. Among patients with triple-class exposed RRMM, the ORR was 100%, with a 70.4% complete response rate and 12-month PFS of 95%. Grade 3/4 infections occurred in 28.6% of patients, but the safety profile — including mild cytokine release syndrome — was manageable. 'JNJ-5322 demonstrated manageable safety and an ORR comparable to CAR T, with convenient, off-the-shelf, weekly dosing, with one step-up dosing to facilitate outpatient dosing,' Popat concluded. Popat, Clavreul, and Kumar reported no relevant financial relationships. Moreaureported honoraria from and advisory board memberships with Janssen, Celgene, Takeda, Amgen, AbbVie, Sanofi, Pfizer, and GSK. Rodriguez Otero reported honoraria from lectures from BMS-Celgene, J&J Innovative Medicines, Sanofi, GSK, Regeneron, and Pfizer; participation in Ad Board meetings for BMS, Janssen, Sanofi, Oncopeptides, Pfizer, Roche, Regeneron, AbbVie, AstraZeneca, H3 Biomedicine, and GSK; consultancy work for BMS-Celgene, AbbVie, Roche, J&J Innovative Medicines, and Pfizer; and research funding and travel support from Pfizer. San Miguel Izquierdo reported participation on advisory boards and consulting services, on behalf of his institution, for AbbVie, Amgen, BMS, Celgene, GSK, Haemalogix, Janssen-Cilag, Karyopharm, MSD, Novartis, Pfizer, Takeda, Regeneron, Roche, Sanofi, Secura Bio, and Gilead-Kite. The two industry-sponsored studies mentioned were funded by Johnson & Johnson.


Gizmodo
an hour ago
- Gizmodo
Surgery Still Beats Ozempic and Other GLP-1 Drugs in Real-World Weight Loss Study
When it comes to weight loss, surgery still reigns supreme. Research out today shows that people undergoing bariatric surgery tend to lose significantly more weight than people taking the newest, most effective GLP-1 medications for obesity. Scientists at New York University conducted the study, which analyzed real-world data from obesity patients. People who received surgery lost five times more weight over a two year span on average than those who were prescribed a GLP-1 drug, they found. The findings also suggest that GLP-1 drugs aren't as effective in the real world as they are in clinical trials, the researchers say. 'I think the takeaway is when you see a new popular drug come out, you have to take it with a grain of salt. And I think you have to wait a few years for the real world data to come out, because it might temper the results you're seeing in trials,' senior study researcher Karan Chhabra, a bariatric surgeon and assistant professor of surgery and population health at the NYU Grossman School of Medicine, told Gizmodo. Bariatric surgery—particularly the sleeve gastrectomy and gastric bypass—has long been considered the most effective treatment for obesity. People usually lose between 20% and 30% of their baseline weight following surgery, and often experience long-lasting improvements in their general health as a result. But in recent years, the emergence of newer GLP-1 drugs like semaglutide (the active ingredient in Ozempic and Wegovy) has dramatically changed the field of obesity medicine. These drugs are typically more effective (and safer) than past nonsurgical obesity treatments, with people on average losing between 10% and 20% of their weight in clinical trials. And they, too, have been associated with health benefits that extend beyond weight loss. At first glance, the data had suggested GLP-1 drugs could approach—or even surpass—the effectiveness of bariatric surgery. But according to Chhabra, there hasn't yet been a rigorous head-to-head comparison of these two different types of obesity treatments among real-world patients. Chhabra and his colleagues examined the anonymous medical records of over 50,000 people who received surgery (either a sleeve gastrectomy or gastric bypass) or GLP-1 therapy (either semaglutide or tirzepatide) through NYU Langone Health or NYC Health + Hospitals between 2018 and 2024. The researchers adjusted for factors like age, starting BMI, and other health conditions to make the two groups comparable. The patients and their weight loss outcomes were tracked for two years. On average, surgical patients lost 58 pounds (around 24% of their total weight) by the end of year two, whereas GLP-1 patients on average lost 12 pounds (around 4.7% of their total weight)—a fivefold difference. The results were slightly better for people who stayed on their medications for a full year (7% weight loss) and for those who took tirzepatide, the newest and most effective GLP-1 drug available (8% to 9%). But the outcomes still fell well short of the success seen with surgery—not to mention the results from earlier clinical trials. The team's findings were presented this week at the annual meeting of the American Society for Metabolic and Bariatric Surgery (ASMBS). There are likely several reasons why these drugs aren't as successful as they've appeared to be in trials, Chhabra noted. As many as 70% of GLP-1 patients discontinue use by the first year, for instance. Some will quit because the side effects, typically gastrointestinal symptoms like nausea and diarrhea, are too much to bear; others may stop simply because they can't afford the drugs any longer (GLP-1 medications often aren't covered by insurance and can cost upwards of $1,000 a month without coverage). Many of the GLP-1 patients in their study also never reached the maximum dose. Chhabra also suspects that many people in the real world aren't getting the supportive care and follow-up they would get from doctors in a clinical trial. GLP-1 drugs have fueled a growing telemedicine industry—for instance, one in which people are often prescribed the medications remotely by medical professionals they'll never interact with personally. (Until recently, people could also easily get compounded versions of semaglutide and tirzepatide, with even less assurance of safety or effectiveness.) The researchers aren't saying that people with obesity shouldn't take GLP-1 drugs, nor that bariatric surgery is the ideal option for everyone. Some people might prefer a one-time treatment, for instance, or may not have the insurance or resources needed to cover long-term GLP-1 therapy. Others may be nervous about going through with any invasive procedure or have other pre-existing conditions that could complicate surgery but not GLP-1 therapy. At the end of the day, people will need to be aware of these treatments' respective pros and cons, and those who choose to go with GLP-1s should manage their expectations, according to Chhabra. 'They have to know that, at least as of now in the real world, their weight loss is not going to be what we're seeing with surgery and they also have to know that it's a lifelong treatment,' he said. 'We don't yet have any protocols for people to maintain weight loss once they've stopped medications so it's important for people to just acknowledge those realities. And I worry that a lot of people are starting medications without really knowing what they're getting into.' The team next plans to sift through more data to figure out exactly why real-life patients on GLP-1 therapy aren't losing as much weight as expected.


CNN
an hour ago
- CNN
Never-before-seen footage shows sun's south pole
Solar Orbiter, a joint mission between NASA and the European Space Agency, is revealing the first-ever views of the sun's south pole. These never-before-seen images offer scientists a chance to better understand our star and its effects on Earth.